MCRB Seres Therapeutics Inc.

6.39
-0.3  -4%
Previous Close 6.69
Open 6.66
Price To Book -8.52
Market Cap 261069259
Shares 40,855,909
Volume 77,509
Short Ratio
Av. Daily Volume 106,600

SEC filingsSee all SEC filings

  1. 8-K - Current report 181197066
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168557
  3. 8-K - Current report 181168131
  4. 8-K - Current report 181166486
  5. 8-K - Current report 181131505

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b trial showed no relevant difference in risk of recurrence compared to placebo - company did note was not powered to detect a statistically significant difference in recurrence rates.
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 3 trial initiation announced June 12, 2017.
SER-109 - ECOSPOR III
Recurrent C. Difficile infection
Phase 1b data released October 2, 2017. Inferior data compared with placebo. Further trial to be initiated mid-2018.
SER-287
Mild-to-Moderate Ulcerative Colitis

Latest News

  1. Edited Transcript of MCRB earnings conference call or presentation 8-Nov-18 1:30pm GMT
  2. Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
  3. Seres Therapeutics (MCRB) Reports Q3 Loss, Misses Revenue Estimates
  4. Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
  5. Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
  6. Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer
  7. New Research Coverage Highlights Altair Engineering, Genomic Health, Seres Therapeutics, REV Group, MACOM Technology Solutions, and New Mountain Finance — Consolidated Revenues, Company Growth, and Expectations for 2018
  8. Seres Therapeutics Sees Hammer Chart Pattern: Time to Buy?
  9. Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018
  10. The Microbiome Therapeutics Innovation Group Announces Coalition Formation and Leadership Team
  11. Edited Transcript of MCRB earnings conference call or presentation 2-Aug-18 12:30pm GMT
  12. Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates
  13. Seres Therapeutics: 2Q Earnings Snapshot
  14. Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
  15. Seres Therapeutics Inc to Host Earnings Call
  16. Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018
  17. Seres Therapeutics to Present at Two Upcoming June Conferences

SEC Filings

  1. 8-K - Current report 181197066
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168557
  3. 8-K - Current report 181168131
  4. 8-K - Current report 181166486
  5. 8-K - Current report 181131505
  6. 8-K - Current report 181051269
  7. 8-K - Current report 18997152
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18987207
  9. 8-K - Current report 18986629
  10. 8-K - Current report 18922135